

## **APPENDIX 12: INTERVENTIONS FOR MANIA – STUDY CHARACTERISTICS**

1.1	Pharmacological interventions.....	2
1.2	Nutritional interventions .....	5
1.3	Physical interventions .....	6

### ***Abbreviations***

AUS	Australia
BEL	Belgium
BGR	Bulgaria
BPI	bipolar I
CHN	China
DEU	Germany
Dur	duration in months
Freq	frequency
HKG	Hong Kong
IND	India
IRN	Iran, Islamic Republic of
ISR	Israel
JPN	Japan
KOR	Korea
N Rand	number of participants randomised
N Post	number of participants at post-treatment
NR	not reported
PHL	Philippines
RUS	Russian Federation
TMS	transcranial magnetic stimulation
TWN	Taiwan
UKR	Ukraine
USA	United States
ZAF	South Africa

## 1.1 PHARMACOLOGICAL INTERVENTIONS

Study <sup>1</sup>	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
<b>Pharmacological interventions</b>											
CIPRIANI2011	NR	NR	NR	NR	NR	1,284	NR	Aripiprazole	30-50 mg	NR	3-6
						379	NR	Asenapine	10-20 mg	NR	3
						315	NR	Carbamazepine	200-1,600 mg	NR	2-6
						59	NR	Gabapentin	600-3,600 mg	NR	3
						1,101	NR	Haloperidol	2-80 mg	NR	2-6
						174	NR	Lamotrigine	50-100 mg	NR	3-6
						912	NR	Lithium	28-1,800 mg	NR	3-6
						1,927	NR	Olanzapine	2-30 mg	NR	3-6
						692	NR	Paliperidone	3-12 mg	NR	3-6
						5,139	NR	Placebo	N/A	NR	3-6
						832	NR	Quetiapine	200-800 mg	NR	3-4
740	NR	Risperidone	1-6 mg	NR	3-4						

<sup>1</sup> Studies are listed alphabetically by drug (group).

*Interventions for mania – study characteristics*

Study <sup>1</sup>	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
						802	NR	Topiramate	50-600 mg	NR	3
						916	NR	Valproate	500-2,500 mg	NR	3-4
						1,033	NR	Ziprasidone	40-160 mg	NR	3

Interventions for mania – study characteristics

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
<b>Pharmacological interventions</b>											
KANBA2012	CHN, HKG, JPN, PHL, TWN	38	59%	100%	Short-acting benzodiazepine and anti-anxiety agents allowed	128	122	Aripiprazole	20 mg	7	3
						130	125	Placebo	N/A	7	3
SZEGEDI2012	AUS, IND, KOR, RUS, THA, USA	39	69%	100%	Lithium or valproate. Benzodiazepines allowed	159	155	Asenapine	12 mg	7	12
						167	163	Placebo	N/A	7	12
ASTRAZENECA2011	BEL, BGR, DEU, IND, RUS, UKR, ZAF	38	38%	100%	NR	173	173	Lithium and quetiapine	450 mg/300 mg	14	6
						183	176	Placebo and quetiapine	300 mg	14	6

## 1.2 NUTRITIONAL INTERVENTIONS

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
<b>Nutritional interventions</b>											
<i>Omega-3 fatty acids compared with placebo</i>											
CHIU2005	CHN	NR	NR	100%	Carbamazepine, lithium or valproate	NR	NR	Eicosapentaenoic acid and docosahexaenoic acid	440 mg/240 mg	14	4
						NR	NR	Placebo	N/A	14	4
<i>Folic acid compared with placebo</i>											
BEHZADI2009	IRN	35	70%	100%	Valproate	44	41	Folic acid	3 mg	7	3
						44	43	Placebo	N/A	7	3

### 1.3 PHYSICAL INTERVENTIONS

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
<b>Physical interventions</b>											
<i>Acupuncture compared with sham acupuncture</i>											
DENNEHY2009A	USA	37	55%	60%	Medication as usual	10	5	Acupuncture	N/A	2	5
						10	7	Sham	N/A	2	5
<i>Transcranial magnetic stimulation (TMS) compared with sham TMS</i>											
KAPTSAN2003	ISR	42	53%	100%	Medication as usual	16	11	TMS	20 minutes	7	2
						9	8	Sham	20 minutes	7	2